Selpercatinib (Retevmo®) Genomic Testing and Management

In an effort to promote higher quality patient care NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Selpercatinib (RETEVMO®) Genomic Testing Management PQI and the Selpercatinib (RETEVMO®) Management PQI, and explores how the medically integrated teams at Moffitt Cancer Center, Smilow Cancer Center at Yale New Haven Health, and Texas Oncology incorporate the information found in the PQIs as part of their daily workflow. This article will discuss how utilizing the Selpercatinib